|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy.
|
26885675 |
2016 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
|
27000758 |
2016 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
|
27014750 |
2016 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
|
27021330 |
2016 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protease inhibitor (PI)-based response-guided triple therapies for hepatitis C virus (HCV) infection are still widely used.
|
25653396 |
2015 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
|
25152985 |
2015 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PegIFNα/ribavirin/protease inhibitor combination is highly effective in severe and/or refractory HCV-MC at the cost of frequent side effects.
|
25135864 |
2015 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Little is known of how patients implement therapy in their daily lives, or of how they deal with these effects.This study aims to describe HCV patients' experiences with protease-inhibitor-based triple therapy and their support needs.
|
25231646 |
2014 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.
|
24801415 |
2014 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed the efficacy and safety of an interferon-free regimen--a fixed-dose combination of the nucleotide polymerase inhibitor sofosbuvir (400 mg) and the HCV NS5A inhibitor ledipasvir (90 mg), with and without ribavirin--in patients with genotype-1 hepatitis C infection who were treatment-naive or previously treated with a protease-inhibitor regimen.
|
24209977 |
2014 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phase 3 trial, Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol-2 (RESPOND-2), demonstrated that the addition of boceprevir (BOC) to peginterferon-ribavirin (PR) resulted in significantly higher rates of sustained virologic response (SVR) in previously treated patients with chronic hepatitis C virus (HCV) genotype-1 infection as compared with PR alone.
|
24041347 |
2013 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previously untreated patients (from the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior therapy (from the Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 [RESPOND-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 28-48 wk).
|
22626609 |
2012 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To examine the usefulness of this human liver-urokinase-type plasminogen activator (uPA)(+/+) severe combined immune deficient (SCID) mouse for the development of HCV-targeted drugs, we evaluated the antiviral efficacy and safety of an HCV NS3-protease inhibitor, BILN 2061.
|
17919490 |
2007 |